VK2735 for Weight Management Phase 3
Launched by VIKING THERAPEUTICS, INC. · Jul 29, 2025
Trial Information
Current as of August 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new medication called VK2735 to see if it can help adults who are overweight or obese lose weight safely and effectively. The study will last about 78 weeks and will compare VK2735 to a placebo (a pill without the active medicine) to understand its effects on weight loss and overall health. The trial is currently looking for adult volunteers who have a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher if they also have at least one weight-related health issue like high blood pressure, high cholesterol, sleep apnea, or certain heart conditions. People with type 2 diabetes are not eligible to join.
If you take part, you’ll be randomly assigned to receive either VK2735 or a placebo, and neither you nor the researchers will know which one you’re getting until the study ends. Throughout the study, your health will be closely monitored to check how well the medication works and to watch for any side effects. The trial excludes people who have had recent significant weight changes, certain medical conditions, or previous weight-loss surgeries or devices. This study aims to find a new option to help people manage their weight and improve their health in a safe, controlled way.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Age ≥18 years of age at the time of signing the informed consent
- • 2. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co- morbid condition (treated or untreated)
- • Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease
- • Cardiovascular disease includes, for example, ischemic cardiovascular disease, New York Heart Association (NYHA) Functional Class I-III heart failure
- • BMI calculated at the Screening visit will be used to determine eligibility
- Exclusion Criteria:
- • 1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation
- • 2. Self-reported body weight change of 5% or more within 3 months of screening
- • 3. Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed \>1 year prior to screening)
- • 4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as, mucosa ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line)
- • 5. Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes)
- • 6. Treatment with glucose-lowering agent(s) within 90 days before screening
- • 7. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
- • 8. History of acute or chronic pancreatitis
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for metabolic and endocrine disorders. With a commitment to advancing innovative treatments, Viking leverages its proprietary drug development platform to address unmet medical needs across a range of conditions, including non-alcoholic steatohepatitis (NASH) and type 2 diabetes. The company's pipeline includes several promising candidates designed to enhance metabolic health and improve patient outcomes. Viking Therapeutics is dedicated to scientific excellence and collaboration, aiming to bring transformative therapies to market for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Birmingham, Alabama, United States
Huntsville, Alabama, United States
Mobile, Alabama, United States
Chandler, Arizona, United States
Flagstaff, Arizona, United States
Scottsdale, Arizona, United States
Tucson, Arizona, United States
Chula Vista, California, United States
Escondido, California, United States
Huntington Park, California, United States
Lake Forest, California, United States
Lemon Grove, California, United States
Lincoln, California, United States
Los Angeles, California, United States
Manteca, California, United States
Montclair, California, United States
Panorama City, California, United States
Rolling Hills Estates, California, United States
San Diego, California, United States
Santa Maria, California, United States
Tustin, California, United States
Van Nuys, California, United States
Walnut Creek, California, United States
Clearwater, Florida, United States
Clearwater, Florida, United States
Cooper City, Florida, United States
Deland, Florida, United States
Delray Beach, Florida, United States
Fort Myers, Florida, United States
Jacksonville, Florida, United States
Lakeland, Florida, United States
Ocoee, Florida, United States
Palmetto Bay, Florida, United States
Port Orange, Florida, United States
West Palm Beach, Florida, United States
Atlanta, Georgia, United States
Columbus, Georgia, United States
Rincon, Georgia, United States
Savannah, Georgia, United States
Woodstock, Georgia, United States
Honolulu, Hawaii, United States
Meridian, Idaho, United States
Chicago, Illinois, United States
Chicago, Illinois, United States
Valparaiso, Indiana, United States
West Des Moines, Iowa, United States
Wichita, Kansas, United States
Lexington, Kentucky, United States
Lexington, Kentucky, United States
Louisville, Kentucky, United States
Baton Rouge, Louisiana, United States
Metairie, Louisiana, United States
Chevy Chase, Maryland, United States
Rockville, Maryland, United States
Methuen, Massachusetts, United States
Ypsilanti, Michigan, United States
Gulfport, Mississippi, United States
Kansas City, Missouri, United States
Saint Peters, Missouri, United States
Springfield, Missouri, United States
Butte, Montana, United States
Omaha, Nebraska, United States
Las Vegas, Nevada, United States
Albuquerque, New Mexico, United States
Albany, New York, United States
Bronx, New York, United States
East Syracuse, New York, United States
Hartsdale, New York, United States
Westfield, New York, United States
Charlotte, North Carolina, United States
Durham, North Carolina, United States
Greensboro, North Carolina, United States
Morehead City, North Carolina, United States
Fargo, North Dakota, United States
Cincinnati, Ohio, United States
Cincinnati, Ohio, United States
Cleveland, Ohio, United States
Columbus, Ohio, United States
Norman, Oklahoma, United States
Tulsa, Oklahoma, United States
Medford, Oregon, United States
Portland, Oregon, United States
East Greenwich, Rhode Island, United States
Myrtle Beach, South Carolina, United States
North Charleston, South Carolina, United States
Knoxville, Tennessee, United States
Nashville, Tennessee, United States
Abilene, Texas, United States
Austin, Texas, United States
Austin, Texas, United States
Brownsville, Texas, United States
Dallas, Texas, United States
Dallas, Texas, United States
Houston, Texas, United States
Lampasas, Texas, United States
San Antonio, Texas, United States
Waco, Texas, United States
Ogden, Utah, United States
Saint George, Utah, United States
Salt Lake City, Utah, United States
Suffolk, Virginia, United States
Renton, Washington, United States
Spokane, Washington, United States
Mayaguez, , Puerto Rico
San Juan, , Puerto Rico
Peoria, Arizona, United States
Long Beach, California, United States
Denver, Colorado, United States
Lakewood Ranch, Florida, United States
New Port Richey, Florida, United States
Lafayette, Louisiana, United States
Boston, Massachusetts, United States
New York, New York, United States
Fayetteville, North Carolina, United States
Morehead City, North Carolina, United States
Portland, Oregon, United States
Greenville, South Carolina, United States
Plano, Texas, United States
San Antonio, Texas, United States
Sandy, Utah, United States
Arlington, Virginia, United States
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported